Redeye provides a brief comment on Ependion’s acquisition of German company Welotec.
Redeye is a bit surprised to hear that CEO Roland Kasper is about to be replaced.
Den 1 april 2025 meddelade AcuCort (”AcuCort” eller ”Bolaget”) att Bolaget mottagit en ny order på Z...
NoHo Partners has executed on its strategy by separating its subcompany Better Burger Society (BBS) ...
Redeye comments on Maximum Entertainment’s announcement regarding notice of default on its US loan w...
Following the many recent grants, notices of allowance and intention to grant patents in Europe and ...
Redeye comments on Physitrack’s announcement regarding the divestment of its German wellness subsidi...
Redeye expects a stable Q1 report from Addnode, with mixed signals in different markets.
Q1'25 numbers due on 29 April at 07:45 CET Adj. EBITDA up by 1% for '25e-'27e Fair value range of SE...
Redeye comments on the takeover offer on Fortnox from First Kraft and EQT X.
Q4 sales pre-announced, SEK -10.7m adj. EBIT in line with ABGSCe Rights issue concluded, 1 Freemelt ...
Redeye comments on Lipigons third quarter report, including positive phase I results for Leaderna, c...
Obducat meddelade den 28 mars år 2025 att Bolaget har erhållit en inköpsorder från en befintlig kund...
Trots en fortsatt substansrabatt på aktien ser vi en attraktiv risk/reward, där den strategiska utve...
Redeye comments on Freemelt’s Q4 results, which were in line with the preliminary figures the compan...
